key: cord-0853360-dlvp79jo
authors: Klimek, Ludger; Pfaar, Oliver; Hamelmann, Eckard; Kleine-Tebbe, Jörg; Taube, Christian; Wagenmann, Martin; Werfel, Thomas; Brehler, Randolf; Novak, Natalija; Mülleneisen, Norbert; Becker, Sven; Worm, Margitta
title: COVID-19 vaccination and allergen immunotherapy (AIT) – A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI)
date: 2021-08-24
journal: Allergol Select
DOI: 10.5414/alx02245e
sha: 55dc60a3c51233e61211aa7af48e5c334112408b
doc_id: 853360
cord_uid: dlvp79jo

Background: Vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response to protect against infection/disease. Allergen immunotherapy (AIT) is thought to induce a (different) immune response, e.g., to induce tolerance to allergens. In this position paper we clarify how to use AIT in temporal relation to COVID-19 vaccination. Four SARS-CoV-2 vaccines are currently approved in the EU, and their possible immunological interactions with AIT are described together with practical recommendations for use. Materials and methods: Based on the internationally published literature, this position paper provides specific recommendations for the use of AIT in temporal relation to a SARS-CoV-2 vaccination. Results: AIT is used in 1) allergic rhinitis, 2) allergic bronchial asthma, 3) insect venom allergy, 4) food allergy (peanut). Conclusion: For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for subcutaneous immunotherapy (SCIT). For sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), we recommend taking them up to the day before vaccination and a break of 2 – 7 days after vaccination. Initiation of a new SCIT, SLIT, or OIT should be delayed until 1 week after the day of the second vaccination. For SCIT, we generally recommend an interval of ~ 1 week to COVID-19 vaccination.

Allergen immunotherapy (AIT) is the only causally effective therapy for which long-term clinical benefit has been demonstrated in allergic respiratory diseases, for example, allergic bronchial asthma or allergic rhinoconjunctivitis and other allergic diseases [1] . Since its first description more than 100 years ago (1911) [2] , AIT has been an established and internationally recognized procedure for the treatment of allergies.

AIT induces immune tolerance to a specific, individually relevant allergen [3] . Sys-tematic meta-analyses have confirmed that AIT significantly reduces symptoms of allergic disease and the amount of necessary antisymptomatic medication in patients with allergic asthma [4] and allergic rhinoconjunctivitis [5] . This is true for both subcutaneous immunotherapy (SCIT) [6, 7] and sublingual immunotherapy (SLIT) [8] .

The risk of patients with allergic rhinitis developing asthma is reduced by AIT [9, 10] . AIT is also effective in patients with IgE-mediated food allergy [11, 12] and insect venom allergy [13] . In addition, the cost-saving effect of this disease-modifying therapeutic option [14, 15, 16] has been demonstrated.

After the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)transmitted corona virus 19 (COVID- 19) infectious disease pandemic in March 2020 [17] , numerous position papers and recommendations for action from international and national allergological societies on the management of allergological diseases and their therapies in the pandemic have been published [18, 19, 20, 21, 22, 23, 24, 25, 26, 58, 59, 60, 61, 62, 63] .

For the two mRNA-based vaccines currently approved in Europe (Comirnaty from BioNTech [27] ; MRNA-1273 from Moderna [28] ) and two vector-based vaccines (CHAdOx1-S from AstraZeneca [29] ; Ad26. COV2-S from Johnson & Johnson [30] ), recommendations for allergological risk assessment of COVID-19 vaccinations have been published in cooperation of AeDA (Ärzteverband Deutscher Allergologen), DGAKI (Deutscher Gesellschaft für Allergologie und Klinische Immunologie), and GPA (Gesellschaft für Pädiatrische Allergologie und Umweltmedizin) [31, 32, 33] .

Based on the technical and directions for use of the four approved COVID-19 vaccines, AIT is not a contraindication [27, 28, 29, 30] .

On this basis, scientific societies have published recommendations for COVID-19 vaccinations for patients undergoing biologic therapy [25, 26, 64] .

The aim of this position paper is to present the use of AIT in its different forms of application (SCIT, SLIT, oral (OIT)) in the context of COVID-19 vaccination and to provide detailed recommendations for action ( Figure 1 ).

AIT attempts to induce a tolerogenic response to an individual antigen dose by continuous administration of that antigen. The main mechanisms include early desensitization of effector cells and progressive onset of a regulatory B and T cell response [34, 35, 36] . Although the main changes of specific immunotherapy are antigen-specific, recent data support a beneficial effect in restoring the general balance of the immune system altered toward Th2 immune response [37, 38] . A recent review analyzes the impact of the COVID-19 pandemic on the management of AIT in routine practice [39] .

Because AIT is administered over a period of several years, there is considerable experience in coadministration with antiviral and other antimicrobial vaccines. Here, negative influences have not become known. On the contrary, immunologically, a restored balance of the innate immune system could improve its protective function [40] .

COVID-19 has caused circa 110 million illnesses worldwide and claimed 2.5 million lives as of the writing of this review [41] .

Effective vaccination against the novel virus represents an essential strategy to achieve maintenance of health care and public life while reducing social constraints [42] .

Four vaccination goals exist in the context of COVID-19 vaccination. Most important is the prevention of severe COVID-19 courses and deaths. In addition, the protection of individuals at particularly high occupational risk of infection, prevention of disease transmission, and maintenance of public life are also important [43] .

Due to extensive collaborations between academia and industry, new vaccine platforms were developed at an unprecedented pace less than a year after the discovery of the SARS-CoV-2 viral sequence, extensively and comprehensively tested in clinical trial programs, and approved (some provisionally or conditionally) after thorough review by regulatory authorities.

Worldwide, 66 COVID-19 vaccines are currently in clinical development and another 176 are in a preclinical development phase [44] .

Vaccines against viral infectious diseases are designed to induce humoral and cellular immune responses against the vaccinated antigen. For this purpose, classical technologies are used, but also vaccine variants that have never been approved for human pharmacology [44] .

The most common route of vaccine application is intramuscular injection, which induces strong priming of dendritic cells. However, vaccines using other routes of application are also currently being developed and their pharmacological properties and ef-fects in terms of immune induction remain to be seen [45] .

Traditionally, either complete viruses are used, or pathoimmunologically significant parts of the virus (for example, those necessary for entry into somatic cells).

The mRNA-based SARS-CoV-2 vaccines from BioNTech/Pfizer and Moderna break new ground in terms of vaccine antigen delivery. BNT162b2 and mRNA-1273 are mRNA-based vaccines that do not introduce the antigen against which an immune response is to be induced (surface protein of the SARS-CoV-2 virus) but the blueprint (the mRNA) to produce the target protein in human cells. Primarily, the mRNA is taken up in muscle cells, but dendritic cells are critically involved in the presentation of the antigen. Regional lymph nodes are then where the immune response predominantly occurs. The target cells produce the viral antigen based on the information of the mRNA by transcription into the amino acid sequence of the protein structure, which becomes visible to the immune system of the vaccinee as a surface protein of such "transduced" cells. The immune system recognizes the surface protein of the SARS-CoV-2 as foreign and starts a humoral and cellular immune response. Degradation products of the produced proteins (peptides) are presented to the T cells, which are thus activated. This enables them to recognize and kill virusinfected cells. Furthermore, activated T cells support the antibody-producing B cells.

Due to the rapid degradation of mRNA, it must be packaged in liposomes as a protective envelope so that uptake into the body's own cells (the transfection) works. Their production has been improved in recent years, but liposomes and the mRNA they contain break down very easily, so these vaccines must be stored at very low temperatures (-20 °C (mRNA-1273) to -70 °C (BNT162b2) between production and use in humans. The lipid nanoparticles and their components also appear to be responsible for the severe allergic reactions to mRNA vaccines [32, 33] .

Vector vaccines are another new class of vaccines. The AstraZeneca vaccine (ChAdOx1-S-(AZD1222)), the vaccine Ad26COV2.S from Janssen Pharmaceutical (Johnson & Johnson), and Sputnik V (Gam-COVID-Vac Adeno-based (rAd26-S+rAdS-S)) from the Moscow Gamaleja Institute are based on harmless human or monkey viruses that are unable to self-replicate and contain the SARS-CoV-2 surface protein [46] .

The adenovirus-based vector vaccines can be stored in the refrigerator at 4 °C for several months without losing their efficacy.

A disadvantage of virus vector vaccines in general is that they cannot be used to vaccinate several times in succession, because the vaccinee develops neutralizing antibodies against the vector itself. As a result, booster vaccinations can be only reduced or no longer effective. This is not a problem with Janssen Pharmaceutical's Ad26COV2.S vaccine, which only needs to be administered once. When booster vaccination is necessary, an alternative strategy in cases of initial immunization with vector virus type A is booster using a heterologous vector type B vaccine. This has already become a reality in the randomized placebo-controlled trial with the Sputnik V vaccine developed in Russia recently [46] .

The type1 allergic reaction is based on a T2 immune response in which immunoglobulin E (IgE) and the cytokines interleukin (IL)-4, IL-5, and IL-13 in particular are significantly involved. From the use of biologics, we know that these key elements of T2 inflammation do not play a role in the antiviral immune response with respect to either IgE or the aforementioned cytokines. The immune response to anti-viral vaccination was not attenuated [47, 48] , whereas anti-IgE treatment increased the production of type 1 interferon from dendritic cells, thereby enhancing the antiviral response [26, 49, 50] .

In principle, manufacturer-specific guidelines Summary of Product Characteristics must be taken into account in the temporal connection of AIT and vaccinations. Thus, there should generally be an interval of ~ 1 week between SCIT and COVID-19 vaccination. Based on experience with other vaccinations, the following procedure has proven effective [25, 40, 51] .

If it is possible to carry out the boosting phase of AIT completely before the planned vaccination date, this can be done as usual, and the recommendations given under "Maintenance therapy" then apply. If vaccination is imminent, initiation of SCIT, SLIT, or OIT should be delayed until 1 week after the second vaccination date [25] .

For continuation of ongoing AIT, we recommend a period of ~ 1 week between SCIT and vaccination, analogous to the above procedure, as well as at least 1 week interval after vaccination, observing the minimum interval between 2 SCIT applications recommended by the manufacturer.

For SLIT or OIT, there are different recommendations from different manufacturers on the interval between vaccination and previous and subsequent SLIT or OIT administration. Therefore, no general recommendation can be given, but the information in the Summary of Product Characteristics should be considered and an individual decision should be made thereafter. In order to be able to limit possible side effects of the SLIT or OIT or the vaccination, we recommend to pause the SLIT or OIT on the day of the vaccination and to continue it with a certain time lag (2 -7 days). In this case, SLIT or OIT can be applied up to the day before the vaccination [25] .

Allergic reactions to vaccines are very rare, occurring at 1 per 1,000,000 -30 per 100,000 vaccinations [52, 53, 54, 55, 56, 57] .

To date, there is no evidence that they are increased under AIT [25, 40] .

Currently, there is no scientifically substantiated evidence for clinically relevant interactions between AIT and the COVID-19 vaccines currently available in Germany.

Both mRNA vaccines against SARS-CoV-2 are based on the same lipid-based nanoparticle carrier technology; the other two vaccines are vector vaccines.

Additional vaccines are expected to be licensed in the coming months, and it is almost inevitable that adverse drug reactions will occur in the coming months that were not observed in the studies conducted for marketing authorization. Such real-life data will play a significant role in assessing interactions with other drugs -including AIT.

Vaccine safety requires a proactive approach to maintain public confidence and reduce reluctance to vaccination among segments of the population. Vigilance, careful response, documentation, and characterization of these events are necessary to allow definition of mechanisms and appropriate approaches for prediction, prevention, and treatment. This is especially true for poten-tial interactions of allergy therapies such as AIT.

This work has been funded by German Allergy Societies AeDA and DGAKI. N. Novak reports honoraria from Alk Abello, Stallergens Geer, Hal Allergy, Leti Pharma, Sanofi Genzyme, Abbvie, Leo Pharma, Novartis, streamed up, and Blueprint outside the submitted work.

The other authors declare no conflicts of interest.

Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper

One hundred years of allergen immunotherapy: time to ring the changes

Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development

Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis

Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis

Development of subcutaneous allergen immunotherapy (part 2): preventive aspects and innovations

Evolution of subcutaneous allergen immunotherapy (part 1): from first developments to mechanism-driven therapy concepts

SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews

Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene

Efficacy, safety, and quality of life in a multicenter, randomized, placebo-controlled trial of low-dose peanut oral immunotherapy in children with peanut allergy

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

Allergen immunotherapy for insect venom allergy: a systematic review and metaanalysis

Health economic analysis of allergen immunotherapy for the management of allergic rhinitis, asthma, food allergy and venom allergy: A systematic overview

International consensus on allergen immunotherapy II: Mechanisms, standardization, and pharmacoeconomics

A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis

COVID-19) weekly epidemiological update and weekly operational update

COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic

COVID-19: pandemic contingency planning for the allergy and immunology clinic

A compendium answering 150 questions on COVID-19 and SARS-CoV-2

COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper

Anwendung von Biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen Covid-19-Pandemiea, b, c: Positionspapier des Ärzteverbands Deutscher Allergologen (AeDA)A, der Deutschen Gesellschaft für Allergologie und klinische Immunologie (DGAKI)B, der Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)C, der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI)D, der Luxemburgischen Gesellschaft für Allergologie und Immunologie (LGAI)E, der Österreichischen Gesellschaft für Pneumologie (ÖGP)F in Kooperation mit der deutschen, österreichischen

Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA: Position paper of the German ARIA GroupA in cooperation with the Austrian ARIA GroupB, the Swiss ARIA GroupC, German Society for Applied Allergology (AEDA)D, German Society for Allergology and Clinical Immunology (DGAKI)E, Society for Pediatric Allergology (GPA)F in cooperation with AG Clinical Immunology

Allergologische Diagnostik und Therapien bei COVID-19 Impfungen: Praktische Handlungsempfehlungen. Empfehlungen von AeDA, DGAKI und GPA

CO-VID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) -A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA)

EMA. Anhang I -Zusammenfassung der Merkmale des Arzneimittels -Comirnaty Konzentrat zur Herstellung einer Injektionsdispersion COVID-19-mRNA-Impfstoff (Nukleosid-modifiziert

Summary of product characteristics: Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified

Summary of product characteristics: COVID-19 Vaccine AstraZeneca suspension for injection

Summary of product characteristics: COV-ID-19 Vaccine Janssen suspension for injection COVID-19 vaccine

Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)

Management von Anaphylaxie gefährdeten Patienten während der Covid-19-Pandemie

Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics

Persistent regulatory Tcell response 2 years after 3 years of grass tablet SLIT: Links to reduced eosinophil counts, sIgE levels, and clinical benefit

Tolerance mechanisms in allergen immunotherapy

Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy

Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response

ARIA-MASK Study Group. Handling of allergen immunotherapy in the CO-VID-19 pandemic: An ARIA-EAACI statement

Allergen-Immuntherapie

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

A guide to vaccinology: from basic principles to new developments

Epidemiologisches Bulletin

Draft landscape and tracker of COVID-19 candidate vaccines

SARS-CoV-2 vaccines in development

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis

ALIZE study investigators. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children

Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma

Allergologie in Zeiten von Covid-19

Vaccine allergy

International Consensus (ICON): allergic reactions to vaccines

Vaccine-associated hypersensitivity

Vaccination and allergy: EAACI position paper, practical aspects

Allergic reactions to vaccines

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update: S2k-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Medical Association of German Allergologists (AeDA), the Society of Pediatric Allergology and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU

Allergic reactions to COVID-19 -vaccinations -unveiling the secret(s)

COVID-19 pandemic and allergen immunotherapy -an EAACI survey

Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021. Epub ahead of print

Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus

Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? Allergy. 2020. Epub ahead of print

Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement